Evidence map›Paper›PMID 37605298›Full record

ArticleAnalytical chemistry2023

Monitoring Metabolic Changes in Response to Chemotherapies in Cancer with Raman Spectroscopy and Metabolomics.

Gabriel Cutshaw, Nora Hassan, Saji Uthaman, Xiaona Wen, Bhuminder Singh, Anwesha Sarkar, Rizia Bardhan

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
10.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Gabriel CutshawDepartment of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 50011, United States.
Nora HassanDepartment of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 50011, United States.
Saji UthamanDepartment of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 50011, United States.ORCID 0000-0001-6387-7510
Xiaona WenNanovaccine Institute, Iowa State University, Ames, Iowa 50012, United States.ORCID 0000-0003-0441-4393
Bhuminder SinghDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Anwesha SarkarDepartment of Electrical Engineering, Iowa State University, Ames, Iowa 50012, United States.ORCID 0000-0002-4267-7242
Rizia BardhanDepartment of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 50011, United States.ORCID 0000-0002-5854-652X
Iowa State University · USVanderbilt University Medical Center · US

Funding

Role of Receptor Tyrosine Kinase cross-talk in colorectal cancerR01CA248505 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SINGH, BHUMINDER · 2021 to 2025
$2.2M
Developing Multimodal Multiplexed ImmunoPET-Raman Probes to Guide ImmunotherapiesR01EB029756 · NIBIB · IOWA STATE UNIVERSITY · PI BARDHAN, RIZIA · 2020 to 2024
$1.2M
PRADA: Portable Reusable Accurate Diagnostics with nanoAntennas for Multiplexed Biomarker Screening of Preterm LaborR21HD100685 · NICHD · IOWA STATE UNIVERSITY · PI BARDHAN, RIZIA · 2020 to 2021
$423k
NCI NIH HHS R01 CA248505NIBIB NIH HHS R01 EB029756NICHD NIH HHS R21 HD100685
6 · The paper itself

Abstract

Resistance to clinical therapies remains a major barrier in cancer management. There is a critical need for rapid and highly sensitive diagnostic tools that enable early prediction of treatment response to allow accurate clinical decisions. Here, Raman spectroscopy was employed to monitor changes in key metabolites as early predictors of response in

Indexed as

Antifibrinolytic AgentsNeoplasmsAmino AcidsCetuximabHumansMetabolomicsOxaliplatinSpectrum Analysis, RamanAmino AcidsAntifibrinolytic AgentsCetuximabOxaliplatin

Identifiers

PMID37605298
PMCPMC10845238
OpenAlexW4386046068

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.